Julie Lucey

Julie Lucey

Auto-generated profile, based on publicly available information

Julie Lucey

Centre for Physics in Health and Medicine, School of Physics, University College Dublin, Ireland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2012 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
VMVinod Mbbch Malik
Vinod Mbbch Malik
CJCiaran Johnston
Ciaran Johnston
CDClaire L Donohoe
Claire L Donohoe
ZCZieta Bsc Claxton
Zieta Bsc Claxton
JLJulie Lucey
Julie Lucey
JRJohn V. Reynolds
John V. Reynolds
Purpose 18F-Fluorodeoxyglucose positron emission tomography (18F-FDG PET) imaging is increasingly the standard of care in the staging of esophageal cancer. Synchronous neoplasms may be identified, and this study evaluated the prevalence of such tumors and their impact on management. Methods Five hundred ninety-one (73.6%) of 803 consecutive patients with biopsy-proven esophageal cancer underwent staging 18F-FDG PET or PET/CT scans. 18F–FDG-avid lesions were considered synchronous primary neoplasms if occurring at locations atypical for metastases from the known primary, a marked discordance in the 18F-FDG avidity from that of the primary tumor, and if there was no prior detection on conventional imaging. Additional investigations as appropriate were undertaken, and histopathological verification was obtained where possible to validate the suspected synchronous neoplasm. Results A synchronous neoplasm was suspected in 55 (9.3%) of 591 patients, predominantly at sites in the colon (26) and head and neck (21). Additional investigations in 43 cases revealed malignant neoplasms in 8 (18.6%), premalignant in 9 (20.9%), and benign lesions in 26 (60.5%) cases. The management plan was altered in 8 patients, 1.4% overall. The total cost of added tests was $27,482.57 (€21,024) with the decision to treat the esophageal cancer deferred by a mean of 10.7 days. Conclusion 18F-FDG uptake concerning for synchronous neoplasms is evident in approximately 1 in 10 cases, and of these a minority will represent a malignant neoplasm that significantly impacts on treatment. The overall added costs per patient are relatively modest and the treatment delay within acceptable limits of clinical practice.

1 September 2019 in Physica Medica
Verified
Journal Article
Closed access
SCSeán Cournane
Seán Cournane
JMJackie McCavana
Jackie McCavana
MMMichael Manley
Michael Manley
LGLinda Gray
Linda Gray
JMJeff McCann
Jeff McCann
JLJulie Lucey
Julie Lucey

12 June 2024 in Physica Medica
Verified
Journal Article
Closed access
LMLorenzo Nicola Mazzoni
Lorenzo Nicola Mazzoni
JDJohn Damilakis
John Damilakis
BGBernard Le Guen
Bernard Le Guen
SHSiamak Haghdoost
Siamak Haghdoost
ARAnnette Röttger
Annette Röttger
SMSusan Molyneux-Hodgson
Susan Molyneux-Hodgson

16 December 2025 in Physica Medica
Verified
Journal Article
Closed access
AMAnn McCann
Ann McCann
MCMathilde Colombie
Mathilde Colombie
LVLuis León Vintró
Luis León Vintró
SCSeán Cournane
Seán Cournane
HAHussein Almeamar
Hussein Almeamar
JLJulie Lucey
Julie Lucey